Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SCG101 |
Synonyms | |
Therapy Description |
SCG101 comprises CD4- and CD8-positive autologous T-lymphocytes engineered to express a T-cell receptor targeting HBsAg, which potentially induce cytotoxicity against tumor cells and enhance antitumor immune activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SCG101 | SCG-101|SCG 101 | SCG101 comprises CD4- and CD8-positive autologous T-lymphocytes engineered to express a T-cell receptor targeting HBsAg, which potentially induce cytotoxicity against tumor cells and enhance antitumor immune activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05417932 | Phase Ib/II | SCG101 | A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma | Recruiting | USA | 2 |